ArticleCancer causes & control : CCC2026
Epidemiological landscape and clinical heterogeneity of primary pancreatic lymphoma: a population-based study.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEpidemiological and clinical characteristics of primary pancreatic lymphoma (PPL) have been rarely reported in the literature. This study aimed to characterize the epidemiological features of PPL and develop robust nomograms for predicting patient survival outcomes.
methodsPatients diagnosed with PPL were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for the period 1983-2015. Incidence rates of PPL were calculated for 1975-2018, and temporal trends were assessed using Joinpoint regression analysis. Cox proportional hazards regression models were applied to identify independent prognostic factors for overall survival (OS) and disease-specific survival (DSS). Nomograms were constructed based on independent clinicopathological factors to predict the probability of survival in PPL patients.
resultsA total of 867 PPL patients were identified between 1983 and 2015, with a mean age at diagnosis of 65.7 years and a male-to-female ratio of 1.5:1. The overall age-adjusted incidence of PPL from 1975 to 2018 was 0.44 per 1,000,000 population, exhibiting a statistically significant increasing trend with an annual percentage change (APC) of 2.33 (95% confidence interval [CI]: 0.88-3.80, P < 0.05). Multivariate Cox regression analysis revealed that age, sex, marital status, pathological subtype, Ann Arbor stage, surgical intervention, and chemotherapy were independent prognostic factors for both OS and DSS (all P < 0.05). Nomograms were developed to predict 1-, 5-, and 10-year OS and DSS, and the predictive performance and calibration of these models were validated using the concordance index (C-index) and calibration curves, respectively.
conclusionPPL is an extremely rare malignancy, yet its incidence has increased steadily over the past four decades. The constructed nomograms can accurately predict 1-, 5-, and 10-year OS and DSS in PPL patients and effectively stratify patients into high-risk and low-risk groups, thus facilitating clinical decision-making.
Indexed as
Identifiers
42420569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.